Financials data is unavailable for this security.
View more
Year on year Capricor Therapeutics Inc grew revenues 886.81% from 2.55m to 25.18m while net income improved from a loss of 29.02m to a smaller loss of 22.29m.
Gross margin | -- |
---|---|
Net profit margin | -102.93% |
Operating margin | -110.50% |
Return on assets | -66.31% |
---|---|
Return on equity | -392.69% |
Return on investment | -208.71% |
More ▼
Cash flow in USDView more
In 2023, Capricor Therapeutics Inc increased its cash reserves by 53.02%, or 5.09m. Cash Flow from Financing totalled 25.58m or 101.60% of revenues. In addition the company used 25.60m for operations while cash from investing totalled 5.11m.
Cash flow per share | -0.8912 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 0.3596 |
---|---|
Tangible book value per share | 0.3596 |
More ▼
Balance sheet in USDView more
Current ratio | 1.37 |
---|---|
Quick ratio | -- |
Total debt/total equity | 0.2935 |
---|---|
Total debt/total capital | 0.2269 |
More ▼